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MINI-FOCUS ISSUE: ELECTROPHYSIOLOGY
CASE REPORT: CLINICAL CASE
A Shocking Case of Far-Field Atrial
Oversensing in Giant-Cell Myocarditis
Tanuka Datta, MD, Stephen Melnick, DO, Bharaniabirami Rajaram, MD, Behzad B. Pavri, MD
ABSTRACT
We report a unique case of delivery of inappropriate implantable cardioverter-defibrillator therapies related to a “perfect
storm”: presence of an integrated lead, insufficient lead slack related to right heart dilation resulting in shock coil
misplacement, myocarditis with loss of R waves, and the concomitant occurrence of an incessant atrial tachycardia.
(Level of Difficulty: Advanced.) (J Am Coll Cardiol Case Rep 2021;3:603–9) © 2021 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
HISTORY OF PRESENTATION
A 35-year-old male with a history of nonischemic
cardiomyopathy from giant-cell myocarditis (GCM)
with a HeartMate 3 left ventricular assist device
(Abbott Cardiovascular, Plymouth, Minnesota) and a
single-chamber implantable cardioverter-
defibrillator (VIGILANT EL ICD D232/254693, Bos-
ton Scientific, Marlborough, Massachusetts) pre-
sented after receiving a shock. His vital signs
showed blood pressure of 110/89 mm Hg, pulse of
69 beats/min, and oxygen saturation of 99% on
room air. Echocardiography showed that his left
ventricle, even when fully unloaded by the left
ventricular assist device with normal flows, was
barely contractile. The right ventricle was also
severely dilated and hypokinetic, suggesting single-
ventricle physiology with the right ventricle acting
as a passive conduit. Telemetry and electrocardio-
graphic review showed an atypical atrial flutter or
atrial tachycardia with predominantly 2:1 atrioven-
tricular block (Figures 1A and 1B).
DIFFERENTIAL DIAGNOSIS
The differential diagnosis for shock therapy included
ventricular tachycardia (VT), ventricular fibrillation
(VF), and inappropriate sensing.
INVESTIGATIONS
Interrogation revealed device programming for VVI
pacing at 40 beats/min. Tachytherapies were pro-
grammed in 2 zones: VT at 200 beats/min (10 s) and
VF at 220 beats/min (2.5 s). Therapies for arrhythmias
in the VT zone were programmed to 2 rounds of
antitachycardia pacing (ATP) followed by 36-J shocks;
LEARNING OBJECTIVES
 To describe clinical scenarios during which
atrial oversensing occurs.
 To recognize the scenario of oversensing of
far-field atrial signals during atrial
tachycardia.
 To identify the mechanism of marked reduc-
tion in ventricular sensed amplitudes in the
setting of myocarditis.
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therapies for arrhythmias in the VF zone
were programmed for 1 try of ATP followed
by shocks. The device logs showed that the
patient had experienced 38 episodes of “VT,”
with 22 episodes triggering ATP and 3 epi-
sodes resulting in shocks; all treated episodes
were declared to have “successful termina-
tion” (Figure 2), all occurring over a short
time period. The stored intracardiac trends disclosed
that over the preceding 2 months, as his steroids were
tapered, the sensed R-wave amplitude had dimin-
ished to the point at which the defibrillator was no
longer able to sense native R waves even at maximum
autogain (Figure 3). However, the far-field atrial
electrograms during ongoing atrial tachycardia were
sensed by the integrated defibrillator lead, leading to
delivery of inappropriate therapies.
MANAGEMENT
In the setting of GCM, the progressive reduction in R-
wave amplitudes was likely due to direct involvement
of the myocardial tissue in the right ventricle, where
his defibrillator lead was located, because of disease
progression. Furthermore, Boston Scientific defibril-
lator leads have an integrated bipolar configuration;
right ventricular (RV) dilation and the septal lead po-
sition (placed at an outside hospital) likely contributed
to the insufficient slack seen on chest radiography,
resulting in the proximal end of the shocking coil (used
as the anode for sensing) being in the right atrium
(Figure 4). The automatic sensing threshold of his
defibrillator had dropped down to the lowest level
because of small native QRS complexes, which resul-
ted in detection of atrial signals during the ongoing
FIGURE 1 Telemetry and Electrocardiography of Atypical Atrial Flutter
(A) Telemetry showing 2:1 atrial tachycardia. Visible atrial deflections are marked with arrows; atrial rate is about 210 to 220 beats/min. (B) 12-Lead electrocardiogram
showing atypical atrial flutter with 2:1 atrioventricular conduction; atrial rate is approximately 216 beats/min, and ventricular rate is about 108 beats/min. Electro-
cardiogram is displayed at twice gain with 20-Hz filter applied.
ABBR EV I A T I ON S
AND ACRONYMS
ATP = antitachycardia pacing
GCM = giant-cell myocarditis
RV = right ventricular
VF = ventricular fibrillation
VT = ventricular tachycardia
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atrial tachycardia at a rate of approximately 210 beats/
min (Figure 5). This arrhythmia was detected as “VT,”
resulting in inappropriate ATP followed by a shock,
terminating the atrial tachycardia briefly.
We tested for true R-wave sensing at maximum
sensitivity of 0.15 mV, but the device continued to
sense only atrial signals. In the setting of inability
to detect true R waves, and inappropriate shocks
due to far-field atrial oversensing during incessant
atrial tachycardia, the device was completely deac-
tivated for both tachycardia and bradycardia
therapies.
DISCUSSION
Inappropriate shocks can be the result of oversensing
atrial depolarization during an atrial arrhythmia such
as flutter or tachycardia (1–3). Clinical scenarios in
FIGURE 2 Device Interrogation Report Showing Ventricular Episodes
FIGURE 3 Progressively Diminishing R-Wave Amplitude Prior to Hospitalization
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which these occur are summarized in Table 1 (4–6). RV
lead positioning becomes especially important with
integrated bipolar leads; placement in the RV apex
with the distal coil lying entirely within the RV cavity
will minimize the probability of atrial oversensing
(7,8). Remote monitoring has the potential to recog-
nize early changes and potentially prevent such out-
comes (9).
FOLLOW-UP
The patient successfully underwent heart trans-
plantation in the following months and is doing well
clinically.
CONCLUSIONS
Inappropriate shocks in the setting of inflammatory
cardiomyopathy can be the result of disease pro-
gression as well as RV lead factors such as bipolar
configurations and lead placement. Cardiologists
must be able to distinguish between true VT and
inappropriate sensing of atrial arrythmias in this
unique setting.
FUNDING SUPPORT AND AUTHOR DISCLOSURES
The authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
FIGURE 4 Implantable Cardioverter-Defibrillator Lead With Insufficient Slack and
Proximal End of Shocking Coil Positioned in the Right Atrium
Arrow denotes proximal end of shocking coil positioned in the right atrium.
FIGURE 5 Intracardiac Signals From Device Interrogation
Intracardiac far-field signals (top trace) and near-field electrograms from the integrated right ventricular lead (bottom trace). No right ventricular signals are visually
evident on the near-field electrograms; a small far-field R-wave is intermittently visible (arrows).
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TABLE 1 Clinical Scenarios During Which Atrial Oversensing Occurs




Lead dislodgement to the atrium or atrioventricular junction Brüggemann
et al. (4)
Integrated bipolar lead positioning near tricuspid annulus Kossaify (5)
Unintentional lead implantation into coronary sinus Gunderson
et al. (6)
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TABLE 1 Continued
Cause of Oversensing Image
First Author
(Ref. #)
Insulation defect in atrial portion of the lead causing sensing of atrial activity Gunderson
et al. (6)
Dual-chamber devices
Atrial lead to RV lead interaction with the atrial lead contacting the RV lead during
atrial systole, thereby producing a signal that is sensed by the RV lead
Gunderson
et al. (6)
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